Procyrion is a technology company.
Procyrion has raised $78.0M across 2 funding rounds.
Procyrion has raised $78.0M in total across 2 funding rounds.
Procyrion is a medical technology company that develops innovative percutaneous mechanical circulatory support (pMCS) devices, primarily targeting heart failure patients. Its flagship product, the Aortix™ device, is a catheter-deployed micro-pump designed to augment cardiac function by pumping blood from the aortic arch to the lower aorta, thereby reducing cardiac workload and improving organ perfusion. Procyrion serves patients with advanced heart failure and cardiorenal syndrome, addressing a critical gap between drug therapy failure and invasive surgical interventions. The company has demonstrated strong growth momentum, evidenced by successful clinical trial enrollments, significant Series E funding rounds, and recognition as a leading medtech innovator[1][2][3][6].
Founded in 2005, Procyrion emerged from the vision of a multidisciplinary team of life science entrepreneurs, engineers, cardiologists, and heart failure specialists dedicated to addressing unmet clinical needs in heart failure treatment. The idea for the Aortix™ device arose from the need for a minimally invasive, catheter-based heart pump that could provide effective circulatory support without the complications of traditional surgical devices. Early traction included winning prestigious awards such as the 2016 PM360 Most Innovative Company and the Johnson & Johnson Quick Fire Challenge, as well as securing residency at JLABS within the Texas Medical Center, which helped accelerate development and clinical validation[4][5].
Procyrion is positioned at the intersection of several critical healthcare trends: the rising prevalence of heart failure and cardiorenal syndrome, the shift toward minimally invasive therapies, and the demand for devices that improve patient outcomes while reducing hospital readmissions. The timing is favorable due to increasing clinical recognition of the limitations of pharmacologic treatments and the high costs associated with advanced surgical interventions. By offering a catheter-based solution that can be deployed quickly and safely, Procyrion influences the broader ecosystem by potentially redefining standards of care for acute decompensated heart failure and cardiorenal syndrome patients[1][3][6].
Looking ahead, Procyrion is poised to advance its pivotal IDE clinical trials and move toward regulatory approvals and broader commercialization. Trends such as aging populations, increasing heart failure incidence, and healthcare systems’ focus on cost-effective, minimally invasive therapies will shape its trajectory. The company’s ability to demonstrate improved patient outcomes and ease of use will be critical to expanding its influence in cardiology and renal care. As Procyrion scales, it may catalyze further innovation in percutaneous circulatory support, potentially transforming treatment paradigms for millions of patients worldwide[3][6].
Procyrion has raised $78.0M in total across 2 funding rounds.
Procyrion's investors include Bluebird Ventures, Chris Schaepe.
Procyrion has raised $78.0M across 2 funding rounds. Most recently, it raised $48.0M Series E in February 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2024 | $48.0M Series E | Bluebird Ventures, Chris Schaepe | |
| Jul 1, 2019 | $30.0M Series D | Bluebird Ventures, Chris Schaepe |